MedTrace Logo

Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in Malawi

NCT02721420 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2018-02-01

No results posted yet for this study

Summary

Background and rationale: Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly 3-day treatment courses of artemether-lumefantrine (AL) in children with severe malarial anaemia prevented 31% of deaths and readmissions. The effect was in addition to the effect of insecticide-treated bednets. There is now need to design and evaluate effective delivery mechanism for PMC within the health system.

Conditions

Interventions

DRUG

dihydroartemisinin-piperaquine

OTHER

message(SMS) reminder

OTHER

Health worker reminder

Health surveillance assistants reminders prior to each treatment course

OTHER

short message(SMS) reminder

Sponsors & Collaborators

  • University of Bergen

    collaborator OTHER

  • The Research Council of Norway

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • Liverpool School of Tropical Medicine

    collaborator OTHER

  • Kenya Medical Research Institute

    collaborator OTHER

  • University of Amsterdam

    collaborator OTHER

  • Imperial College London

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • University of Minnesota

    collaborator OTHER

  • Ministry of Health and Population, Malawi

    collaborator OTHER_GOV

  • Ministry of Health, Malawi

    collaborator OTHER_GOV

  • Kamuzu University of Health Sciences

    lead OTHER

Principal Investigators

  • Kamija Phiri, PhD · University of Malawi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
4 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-24
Primary Completion
2019-03-31
Completion
2019-12-31

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02721420 on ClinicalTrials.gov